For Patients For Caregivers For Medical Professionals

HELPLINE 1-800-465-4837
Mon-Fri 9am – 5pm EST

ALF at 40
04 AUGUST 2017

ALF at 40

Happy New Year! This is the first issue of Liver Lowdown in 2016. This year, the American Liver Foundation (ALF) will celebrate four decades of providing help and hope to those who are battling liver disease.

Today’s issue focuses on research. Certainly, the last 40 years of medical research has resulted in improvements in the survival and quality-of-life of those battling liver disease. Hepatitis B vaccines went into widespread usage in the 1970’s and are readily available in the United States, living-donor liver transplants are increasingly more common (first successfully performed in 1989), and a cure for hepatitis C is finally here.

As you will read today, the progress has not slowed. In this issue, we report on advances in research on Primary Biliary Cholangitis (PBC), Primary sclerosing cholangitis (PSC), Fatty Liver Disease and other conditions.

You may find today’s issue more technical than past editions. In many cases, we use the language of those conducting the research to describe their work. Each of the studies discussed was presented at The Liver Meeting, one of the world’s largest conferences on liver research.

We hope that you find this issue as inspiring as we do. Thanks to the work of so many research teams, better treatments and potential cures for an array of conditions may be just around the corner. We also thank you for supporting the American Liver Foundation and for helping us to make grants to over 800 liver researchers.

Share this page

Comments are closed.